Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ASTRAZENECA - PRODUTOS FARMACÊUTICOS LDA

NIF 502942240
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €7,871,909 81 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €7,871,909 81 contracts
A2 · Late Publication €12,855,230,604 3,423 contracts
Contract published to BASE more than 10 days after the signing date
LOW €12,855,230,604 3,423 contracts
A5 · Threshold Splitting €132,105,465 156 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €132,105,465 156 contracts
A6 · Low Competition €13,406,174 77 contracts
Only one bidder participated in a competitive procedure
MEDIUM €13,406,174 77 contracts
A9 · Price Overrun €128,127 2 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €128,127 2 contracts
A9 · Abnormal Price Reduction €15,665,250,986 1,507 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €15,665,250,986 1,507 contracts
C3 · Missing Mandatory Fields €17,848,995 105 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €17,848,995 105 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

523
€2,438,179,887
175
€541,415,316
263
€535,527,239
540
€523,782,502
84
€523,147,844
133
€506,771,070
76
€505,055,531
39
€497,653,198
77
€494,893,454
180
€474,961,734
67
€464,936,894
56
€457,113,762
231
€416,349,964
36
€411,304,807
37
€402,811,058
68
€399,098,090
172
€369,612,930
73
€354,642,361
139
€342,281,870
32
€326,257,118
Page 1 of 4 · 70 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 4 · 156 contracts

61/1184/2026 - Medicamento Ciclossilicato de zircónio sódico 10 g Pó susp oral Saq
PT · 13635839 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,879 2026-02-12
TREMELIMUMAB 20MG Sol inj Fr 15 ml IV
PT · 13143077 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,000 2026-02-03
OLAPARIB 100 MG COMP E TRASTUZUMAB EMTANSINA 100 MG PÓ CONC SOL INJ FR IV
PT · 12198516 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€74,830 2025-12-23
TREMELIMUMAB 20 MG/ML SOL INJ FR 15 ML IV
PT · 12401194 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-12-16
Aquisição de Benralizumab 30 mg/1ml Sol Inj CAN SC ao abrigo do Acordo Quadro 2024/0899
PT · 13281826 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€73,476 2025-12-04
TREMELIMUMAB 20 MG/ML SOL INJ FR 15 ML IV
PT · 12496622 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-11-10
Q1/2318/2025 - AGREGAÇÃO URGENTE - MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 11952203 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,294,078 2025-10-22
11/04086.11/2025 - Aquisição de Tremelimumab 20 mg/ml Sol inj Fr 15 ml IV
PT · 11818247 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,000 2025-10-22
1573525 - TREMELImumab 20 mg/ml Sol inj Fr 15 ml IV
PT · 12206807 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-09-30
Aquisição do medicamento TREMELIMUMAB 20 MG/ML SOL INJ Fr 15ml IV
PT · 11683887 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,000 2025-09-05
Aquisição do Medicamento Anifrolumab [150 Mg/Ml; 1 Fr 2 Ml] para a ULSCB
PT · 11665828 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,385 2025-08-27
AE/2385/2025 - TREMELIMUMAB 20MG/ML INJ 15ML
PT · 11642558 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,000 2025-08-12
1619725 Aquisição de Tremelimumab 20 mg/ml Novo doente autorizado
PT · 11632262 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,000 2025-08-08
TREMELIMUMAB 20MG
PT · 11633010 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,000 2025-08-08
TREMELIMUMAB 20 MG/ML SOL INJ FR 15 ML IV para as necessidades imediatas - C. Prev. 91129625
PT · 11654740 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-08-08
TREMELIMUMAB 20 MG/ML SOL INJ FR 15 ML IV para as necessidades imediatas - AD 92129525
PT · 11662968 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-07-18
ADCM3064/25 - MEDICAMENTOS DIVERSOS
PT · 11616081 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€149,723 2025-07-11
TREMELIMUMAB + CICLOSSILICATO DE ZIRCÓNIO SÓDICO - 10000015102025
PT · 11643748 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€144,496 2025-07-02
ADCM 3027/25 - medicamentos diversos
PT · 11564198 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€4,881 2025-07-02
Aquisição do Medicamento TEZEPElumab de Fornecimento Exclusivo do Laboratório Astrazeneca: Ano 2025
PT · 11521336 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€145,766 2025-06-16
AD/582/2025 - Fornecimento de substância ativa: Tremelimumab 300 MG (15 ML)
PT · 12007776 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-06-16
41008725 - TREMELIMUMAB 20 MGML SOL INJ FR 15 ML IV
PT · 11530269 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-06-12
Aquisição de Tremelimumab 20 mg/ml Sol inj Fr 15 ml IV
PT · 11521852 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-05-27
TREMELIMUMAB 20 MG/ML SOL INJ FR 15 ML IV
PT · 11767560 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,000 2025-05-14
VÁRIOS MEDICAMENTOS
PT · 11316574 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award
€19,154 2025-03-25
AQUISIÇÃO DE CICLOSSILICATO DE ZIRCÓNIO SÓDICO 5 G PÓ SUSP ORAL SAQ
PT · 10978834 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€74,800 2024-10-17
VÁRIOS MEDICAMENTOS
PT · 10939039 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,555 2024-09-24
241G001365 - Ciclossilicato de zirconio sodico 10 g p
PT · 10905071 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,879 2024-09-06
MEDICAMENTOS
PT · 10914527 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€19,659 2024-09-04
J1/2541/2024 ANDEXANET ALFA 200MG PÓ P/ SOL P/ PER
PT · 10921065 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€144,000 2024-08-29
BENRALIZUMAB 30MG/1ML CANETA PRÉ-CHEIA (PC.02033.2024)
PT · 10829733 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€73,476 2024-06-27
OSIMERTINIB 40 MG COMP
PT · 11167265 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€149,357 2024-06-13
VÁRIOS MEDICAMENTOS
PT · 10767557 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,694 2024-06-05
VÁRIOS MEDICAMENTOS
PT · 10769824 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,694 2024-06-05
BENRALIZUMAB 30 MG/1 ML SOL INJ CANETA 1 ML SC
PT · 11124400 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€73,476 2024-05-08
Acordo quadro para suficientes de Medicamentos do Aparelho Respiratório, às Instituições e Serviços do Serviço Nacional de Saúde
PT · 10662671 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€148,967 2024-04-04
VÁRIOS MEDICAMENTOS
PT · 10601496 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,617 2024-03-05
Q1/682/2024 - MEDICAMENTOS DIVERSOS
PT · 10596339 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€73,383 2024-03-04
Acalabrutinib 100 mg Comp. revestido
PT · 10615168 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,826 2024-01-26
Fornecimento de substância ativa: Acalabrutinib 100 mg
PT · 10353158 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€144,781 2023-11-17
MEDICAMENTOS
PT · 10295136 · Ajuste Direto Regime G...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€73,656 2023-10-11
MEDICAMENTOS
PT · 10084049 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,991 2023-06-07
P1153 -10121776 - PALIPERIDONA 175 MG SUSP INJ LP SER 0,875 ML IM - CPA 19/2022
PT · 11634273 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,942 2023-05-29
Goserrelina 10.8 mg Impl Ser SC, Budesonida 1 mg/2 ml Susp inal neb Fr 2 ml
PT · 10179457 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,645 2023-05-18
Paliperidona 175 mg Susp inj LP Ser 0.875 ml IM
PT · 11045178 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,942 2023-05-10
AQUISIÇÃO DE MEDICAMENTOS DO GRUPO 4: SANGUE AO ABRIGO DO ACORDO QUADRO 2020/018 DOS SPMS, EPE
PT · 9985720 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€143,453 2023-05-09
Medicamentos do grupo 4 (Sangue)
PT · 10247326 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€147,916 2023-05-03
DS_06/00053.11/2023 - Aquisição de medicamentos do Grupo 4 Sangue
PT · 9872945 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€147,428 2023-03-14
231000195 - Medicamentos do CPA 2020/18
PT · 9860875 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€73,015 2023-03-14
231000030/13559 - VÁRIOS MEDICAMENTOS
PT · 9809845 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€147,875 2023-01-31
Next →
Overview
Total Value Won
€15,882,783,063
Contracts Won
4,775
Score 165250 · CRITICAL RISK
NIF
502942240
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • E.J. [P-13b7]
    Gerente
    since 2010-09-23
  • G.N. [P-2825]
    Gerente
    since 2008-06-17
  • J.B. [P-80c4]
    Gerente
    since 2008-06-17
  • M.D. [P-18ef]
    Gerente
    since 2022-08-01
  • M.J. [P-958d]
    Gerente
    since 2020-02-10
  • N.P. [P-b3fe]
    Gerente
    since 2025-07-07
  • A.R. [P-e93b]
    Gerente
    2016-01-04 → 2017-01-31
  • A.L. [P-4505]
    Gerente
    2011-02-09 → 2014-04-02
  • C.S. [P-8924]
    Gerente
    2019-07-01 → 2021-02-01
  • D.R. [P-d3ac]
    Gerente
    2012-03-19 → 2015-05-21
  • E.J. [P-13b7]
    Gerente
    until 2012-03-19
  • G.N. [P-2825]
    Gerente
    until 2011-05-27
  • J.P. [P-7a84]
    Gerente
    2015-05-21 → 2019-07-01
  • J.F. [P-52bd]
    Gerente
    2012-07-24 → 2015-05-21
  • J.B. [P-80c4]
    Gerente
    until 2010-09-23
  • M.D. [P-18ef]
    Gerente
    2017-01-31 → 2020-02-10
  • M.M. [P-af72]
    Gerente
    2020-02-10 → 2022-08-01
  • M.P. [P-6a2e]
    Gerente
    until 2011-02-09
  • M.P. [P-6a2e]
    Gerente
    2011-05-27 → 2012-07-24
  • M.P. [P-6a2e]
    Gerente
    2014-04-02 → 2016-01-04
  • P.M. [P-5912]
    Gerente
    2015-05-21 → 2020-02-10
  • S.P. [P-a960]
    Gerente
    2021-02-01 → 2025-07-07
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned